Stock Ratings / Health Care / JSPR / financials

SCLX (52) PLUR (39) DYAI (33) BCDA (49) ⌘ Pro Terminal →

Jasper Therapeutics Inc. (JSPR) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.53 -1.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.53

Jasper Therapeutics Inc. (JSPR) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $17.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.53 (-0.42%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JSPR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY JSPR SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (29% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.57-15.8% Next Q

Q2 (-2Q)

Grade D$0.48+6.3% Next Q

Q3 (-1Q)

Grade D$0.51+3.9% Next Q

Current

Grade D-$0.53-7.2% Hist 90D α

Trajectory: D (49) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a JSPR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While JSPR currently carries a cautious 41/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.60) and Max Pain ($0.56) forces dealer call-delta covering toward $2.54.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $JSPR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “JSPR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How JSPR Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-2.1%	-$76	-$77.2M	-45%
FY 2024	$4.00B	52%	-1.9%	-$71.3M	-$62.6M	-45%
FY 2023	$4.00B	52%	-1.7%	-$64.5M	-$52.1M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JSPR)

✓Walkthrough of JSPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

JSPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -43.62%📐 HORIZONTAL RANGE

2026-10-30O $0.52H $0.55L $0.51C $0.53VOL 396.0K

RES: $1.03SUP: $0.45SMA50: $0.60SMA200: $0.85

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

JSPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 JSPR Butterfly Map → + Track JSPR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on JSPR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for JSPR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for JSPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JSPR)

Health Care Rank #624 of 1016 ⚔️ SCLX vs JSPR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (JSPR vs. SCLX, PLUR, DYAI, BCDA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Jasper Therapeutics Inc. (JSPR) ranks #624 by composite RQD confidence (41/100, grade D-) and #841 by equity capitalization ($17.7M). Within this direct 5-issuer industry benchmark cohort, JSPR leads on earnings valuation at N/A trailing P/E, while JSPR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SCLX currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with JSPR at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
JSPR ACTIVE Jasper Therapeutics Inc.	D-	41/100	—	—	-35.0%	-1.26%	$17.7M	Benchmark Subject
SCLX Scilex Holding Company	D+	52/100	—	96.0%	-35.0%	-1.43%	$17.5M	/sclx-vs-jspr →
PLUR Pluri Inc.	D-	39/100	—	49.0%	-35.0%	-2.44%	$16.1M	/plur-vs-jspr →
DYAI Dyadic International Inc.	E	33/100	—	24.9%	-35.0%	-8.40%	$14.5M	/dyai-vs-jspr →
BCDA BioCardia Inc.	D	49/100	—	—	-35.0%	-2.26%	$14.0M	/bcda-vs-jspr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001788028

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Jasper Therapeutics Inc. (JSPR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$76, operating cash flow of -$77.2M, and free cash flow of -$77.2M (-23.3% YoY). On the balance sheet, JSPR closed FY2025 with $35.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$76	-$77.2M	-$77.2M	$35.8M	—
FY2024 (FY)	2024-12-31	$0	-$71.3M	-$62.6M	-$62.6M	$79.9M	—
FY2023 (FY)	2023-12-31	$0	-$64.5M	-$52.1M	-$52.1M	—	—

3. JSPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is JSPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Jasper Therapeutics Inc. (NASDAQ: JSPR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.53 (-1.26% 1D, market cap $17.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, JSPR ranks #624 in composite RQD confidence.

How does JSPR compare to SCLX and PLUR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), JSPR carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SCLX (Scilex Holding Company) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $17.5M) and PLUR (Pluri Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M). Among the 5-stock peer group, JSPR leads on earnings multiple (N/A) while JSPR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for JSPR?

Per JSPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001788028), Jasper Therapeutics Inc. generated $0 in revenue, -$76 in net income, and -$77.2M in free cash flow against $35.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is JSPR trading relative to its 50-day, 200-day, and 52-week technical levels?

JSPR last traded at $0.53 (-1.26% on volume of 413,083 shares), positioning the stock -11.67% below its 50-day simple moving average ($0.60) and -37.65% below its 200-day simple moving average ($0.85). Across its 52-week range of $0.32 to $2.42, JSPR sits at the 10.0% percentile with a 14-day RSI of 44.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.60).

JSPR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Jasper Therapeutics Inc. (JSPR)?

In FY 2025 (10-K), JSPR converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: JSPR RQD Cockpit JSPR 12M Forecast JSPR Earnings & Move JSPR Dividends & DRIP JSPR Insiders & 13F JSPR Whale Options JSPR Profit Sankey JSPR News & Why